Last reviewed · How we verify
Clostridium difficile Toxoid Vaccine
At a glance
| Generic name | Clostridium difficile Toxoid Vaccine |
|---|---|
| Also known as | ACAM-CDIFF™ |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults (PHASE1, PHASE2)
- Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study (PHASE3)
- Clostridium Difficile Vaccine Efficacy Trial (PHASE3)
- Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age (PHASE3)
- Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection (PHASE3)
- Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults (PHASE2)
- Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan (PHASE1, PHASE2)
- Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: